GH Research (NASDAQ:GHRS) Given New $39.00 Price Target at Citizens Jmp

GH Research (NASDAQ:GHRS) had its price objective decreased by Citizens Jmp from $42.00 to $39.00 in a report issued on Friday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

A number of other research analysts have also commented on GHRS. Needham & Company LLC lifted their price objective on shares of GH Research from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Guggenheim set a $34.00 price target on shares of GH Research and gave the company a “buy” rating in a report on Tuesday, March 10th. Citigroup reaffirmed an “outperform” rating on shares of GH Research in a report on Friday. HC Wainwright upped their price target on shares of GH Research from $35.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Finally, Royal Bank Of Canada upped their price target on shares of GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, GH Research has an average rating of “Moderate Buy” and an average target price of $41.00.

GH Research Stock Down 3.7%

Shares of GH Research stock opened at $21.39 on Friday. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -23.25 and a beta of 1.27. The business has a 50-day moving average price of $17.14 and a 200-day moving average price of $15.53. GH Research has a twelve month low of $10.66 and a twelve month high of $24.66.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). On average, equities analysts expect that GH Research will post -1.52 EPS for the current fiscal year.

Institutional Investors Weigh In On GH Research

Institutional investors have recently bought and sold shares of the business. HighVista Strategies LLC grew its stake in GH Research by 363.0% during the third quarter. HighVista Strategies LLC now owns 241,894 shares of the company’s stock worth $3,459,000 after buying an additional 189,647 shares during the period. CenterBook Partners LP purchased a new position in shares of GH Research in the third quarter valued at $2,376,000. AdvisorShares Investments LLC boosted its stake in shares of GH Research by 41.1% in the third quarter. AdvisorShares Investments LLC now owns 53,991 shares of the company’s stock valued at $772,000 after purchasing an additional 15,735 shares during the period. Barclays PLC boosted its stake in shares of GH Research by 63.4% in the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after purchasing an additional 822 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of GH Research in the first quarter valued at $290,000. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.